PSMA-Directed Therapies in Prostate Cancer

April 2, 2014
Daniel P. Petrylak, MD

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses PSMA and its role in prostate cancer treatment.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses PSMA and its role in prostate cancer treatment.

Clinical Pearls:

  • PSMA (Prostate Specific Membrane Antigen) is a protein distinct from PSA in that it is a folate transporter and is expressed in about 90% of prostate cancer specimens
  • PSMA seems to be upregulated after hormone therapy and may be downregulated as patients progress in the pathway of castration resistance
  • PSMA is a target of ProstaScint, an FDA approved agent for imaging prostate cancer
  • PSMA is being used as an imaging agent and a therapeutic target
  • Researchers have been looking into combining anti-PSMA antibody with an agent that targets tubulin, which may deliver chemotherapy more effectively
  • The anti-PSMA antibody has demonstrated activity in patients who failed docetaxel and cabazitaxel